Evidence map›Paper›PMID 17407575›Full record

ArticleBMC cancer2007

Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks.

Heiko Fensterer, Bernhard Radlwimmer, Jörn Sträter, Malte Buchholz, Daniela E Aust, Catherine Julié, François Radvanyi, Bernard Nordlinger, Claudio Belluco, Eric Van Cutsem and 8 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyValidation Study
In one paragraph

Article in BMC cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00004150 (Pan-European Trials in Adjuvant Colon Cancer), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00004150 phase3completednot on this map

Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid

TypeinterventionalSponsorRobert Roessle KlinikRan1999 to 2007ConditionsColorectal CancerArmsfluorouracil, leucovorin calcium, adjuvant therapy
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Genetics, cytogenetics, and epigenetics of colorectal cancer.Journal of biomedicine & biotechnology · 2011
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 3 countries.

Heiko FenstererDepartment of Internal Medicine I, University of Ulm, Ulm, Germany. heiko.fensterer@med.uni-marburg.de <heiko.fensterer@med.uni-marburg.de>
Bernhard Radlwimmer
Jörn Sträter
Malte Buchholz
Daniela E Aust
Catherine Julié
François Radvanyi
Bernard Nordlinger
Claudio Belluco
Eric Van Cutsem
Claus-Henning Köhne
Hans A Kestler
Carsten Schwaenen
Michelle Nessling
Manfred P Lutz
Peter Lichter
Thomas M Gress
EORTC Gastrointestinal (GI) Group
German Cancer Research Center · DEPhilipps University of Marburg · DEUniversität Ulm · DEHôpital Ambroise-Paré · FRCentre National de la Recherche Scientifique · FRcts CaritasKlinikum Saarbrücken · DEIstituti di Ricovero e Cura a Carattere Scientifico · ITKlinikum Oldenburg · DETechnische Universität Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe identification of genomic signatures of colorectal cancer for risk stratification requires the study of large series of cancer patients with an extensive clinical follow-up. Multicentric clinical studies represent an ideal source of well documented archived material for this type of analyses.

methodsTo verify if this material is technically suitable to perform matrix-CGH, we performed a pilot study using macrodissected 29 formalin-fixed, paraffin-embedded tissue samples collected within the framework of the EORTC-GI/PETACC-2 trial for colorectal cancer. The scientific aim was to identify prognostic genomic signatures differentiating locally restricted (UICC stages II-III) from systemically advanced (UICC stage IV) colorectal tumours.

resultsThe majority of archived tissue samples collected in the different centers was suitable to perform matrix-CGH. 5/7 advanced tumours displayed 13q-gain and 18q-loss. In locally restricted tumours, only 6/12 tumours showed a gain on 13q and 7/12 tumours showed a loss on 18q. Interphase-FISH and high-resolution array-mapping of the gain on 13q confirmed the validity of the array-data and narrowed the chromosomal interval containing potential oncogenes.

conclusionArchival, paraffin-embedded tissue samples collected in multicentric clinical trials are suitable for matrix-CGH analyses and allow the identification of prognostic signatures and aberrations harbouring potential new oncogenes.

Indexed as

Gene Expression ProfilingNucleic Acid HybridizationClinical Trials as TopicColorectal NeoplasmsDissectionFixativesFormaldehydeHumansIn Situ Hybridization, FluorescenceParaffin EmbeddingPilot ProjectsPrognosisRisk AssessmentSpecimen HandlingFixativesFormaldehyde

Identifiers

PMID17407575
PMCPMC3225877
OpenAlexW2007254690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.